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ABSTRACT 
Diabetes Mellitus is a globally recognized chronic multifactorial progressive disease marked by 
elevated levels of sugar in the blood. It affects approximately 8.5% of the adult population in the 
world. Metabolic and hereditary factors along with ageing and obesity are the driving forces 
behind it. The actual prevalence of diabetes is relatively high because more than 50% diabetics 
are not diagnosed until ten years after onset of the disease. This review focuses on the causes, 
types, complications along with its management and treatment.  
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1) INTRODUCTION 
Historically, Egyptians firstly recognized diabetes mellitus 
with the usual symptoms of weight loss with frequent 
urination reflexes. The word “diabetes” is derived from a 
Greek term for passing through, a reference to increased 
urination a common symptom of the disease. “Mellitus” is the 
Latin word for honey, a reference to glucose noted in the urine 
of diabetic patients. Diabetes Mellitus manifests as a chronic 
global epidemic disease as evident from recent WHO reports 
indicating more than 1.6 million deaths annually due to 
diabetes. 7% of deaths among men aged 20–69 and 8% among 
women aged 20–69 occur due to diabetes at global level. The 
estimated number of people with diabetes has jumped from 
108 million in 1980 to 422 million in 2014. Its global 
prevalence expected to increase from 4.7% in 1980 to 8.5% by 
the year 2014 as predicted by recent surveys. The actual 
prevalence of diabetes is relatively high because more than 
50% diabetics remain undiagnosed. Its prevalence has 
increased rapidly in low and middle income countries in last 
three decades [1]. Diabetic patients are prone to both short-
term and long-term complications facilitating chronic health 
problems and premature deaths, nearly 1 death every 10 
seconds [2].The root causes of diabetes mellitus are unhealthy 
lifestyle factors such as overeating, physical inactivity, obesity 
or uncontrollable risk factors including genetics, family 
history and age. Diabetes not only affects humans but also 
other mammals like dogs, cats and other animals [3]. 
 
2) PATHOPHYSIOLOGY OF DIABETES MELLITUS 
 
A healthy physiological state in the human body is maintained 
by the differential and effective functioning of all the organ 
systems. Any deviation from their normal functioning led to 
the development of disorder or pathological state. Diabetes 
mellitus is one of the pathological condition in which body 
fails to maintain normal glucose level in the blood stream due 
to inability of the body to make or use insulin hormone. 
Insulin is needed for glucose transport into the cells so they 
can metabolize. The common symptoms of diabetes mellitus 
are hyperglycemia, polydipsia, polyuria, dehydration, 
polyphagia, ketoacidosis, impaired vision, increased 
susceptibility to infections, delayed healing of sores, fatigue, 
lethargy or dizziness.  
2.1. BLOOD GLUCOSE REGULATION MECHANISM: 
Being the primary respiratory substrate, Glucose is normally 
found in the blood. When its concentration in the blood 
exceeds beyond 126 mg/dl of the blood volume (abbreviated 
as FBS/FPG, Fasting blood sugar/Fasting plasma glucose) 
before a meal or 200 mg/dl of the blood volume after a meal 
(abbreviated as RBS, Random blood sugar), the person is said 
to be hyperglycemic or diabetic. There are two major 
hormones namely insulin and glucagon which act 
antagonistically in order to maintain normal blood glucose 
level. An increase in the blood glucose level stimulates the β 
cells of islets of langerhans of pancreas to secrete insulin 
hormone which in turn causes the  transport of glucose into the 
liver cells where glucose get converted into the glycogen, the 
reserve food molecule. Insulin is a 51 amino acid containing 
polypeptide hormone consisting of two chains A and B which 
are connected by disulphide bonds. It is firstly secreted in an 
inactive form pro‑insulin having three chains- A, B and C and 
thereafter it is converted into active form by the enzymes 
convertases and carboxypeptidase. The insulin is the carried 
by the blood to the liver cell where it binds to the tyrosine 
kinase insulin receptor which is made up of two α subunits 
(extracellular) and two β subunits (intramembrane) linked by 
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disulfide bonds. It results into autophosphorylation of the β 
subunit which is then followed by conversion of excess 
glucose to glycogen for storage [4]. Adipose and skeletal 
muscle cells also get stimulated to uptake more glucose by the 
translocation of glucose transporter (GLUT4) to the cell 
surface. This control mechanism normalizes blood glucose 
concentration. At low blood glucose level, α cells of pancreas 
are stimulated to release glucagon. Glucagon signals the liver 
cells to convert stored glycogen into glucose which is then 
released into the blood to achieve homeostasis. In diabetes 
mellitus, there is a defect either in the synthesis or secretion of 
insulin as seen in type 1 diabetes mellitus (T1DM) or the 
development of resistance to insulin as in the case of type 2 
diabetes (T2DM).  
 
2.2 TYPES OF DIABETES MELLITUS: There are 
different variants of Diabetes Mellitus available in the 
population like type 1 diabetes mellitus (T1DM) type 2 
diabetes mellitus (T2DM), Gestational diabetes (GD)  
Maturity onset diabetes of the young (MODY) and Latent 
autoimmune diabetes in adults (LADA). 
 
2.2.1 TYPE 1 DIABETES MELLITUS: T1DM previously 
known as insulin-dependent, juvenile or childhood-onset 
diabetes usually occurs in childhood and early adulthood (<35 
years). It may be due to genetic and environmental factors. 
HLA gene present on chromosome 6 code for HLA proteins 
on the cell surfaces. These proteins are responsible for 
recognition of self or nonself by immune system. Any defect 
in the HLA gene results into encoding of defective HLA 
proteins that triggers autoimmune response of the immune 
cells against the β cells of pancreas. Activated CD4+ and CD8+ 
T cells and macrophages infiltrating the pancreatic islets 
attacks on β cells of pancreas and destroy them [5]. In African 
and Asian populations another rare form of T1DM, called 
idiopathic diabetes that does not involve autoimmunity is 
found due to the less insulin production [6].Regular 
Administration of insulin becomes mandatory in this case to 
maintain glucose balance in the body for survival. In some 
cases, Type 1 diabetic patients develop insulin resistance due 
to genetic reasons or weight gain leading to development of 
double diabetes condition. Polyuria, polyphagia and increased 
thirst, loss of weight, weakness and fatigue are the common 
symptoms of type 1 diabetes. 
 
2.2.2 TYPE 2 DIABETES MELLITUS: It is the most 
common type of diabetes worldwide accounting for 90% of 
diabetic cases, as per reports of NIH, USA. It has been 
reported that type 2 diabetes in obese persons develops 
resistance to endogenous insulin due to changes in the cell 
receptors associated with the deposition of abdominal fat 
whereas in non‑obese persons, insulin inefficiency has been 
seen at the post receptor levels in addition to a deficiency in 
insulin production and release. Overweight and obesity are the 
strongest risk factors for type 2 diabetes. Physical inactivity 
along with a diet that is high in calories, processed 
carbohydrates and saturated fats and insufficient in fibre rich 
whole foods are promoters of type 2 diabetes. Common 
symptoms of type 2 diabetes are blurred vision, slow healing 
of sores, irritability, tingling in hands or feet and frequent 
infections of bladder, vagina and skin [7]. 
2.2.3 GESTATIONAL DIABETES: During pregnancy 
period, females show great deal of glucose fluctuation and 
often experience accelerated starvation. It raises the glucose 
concentration in the blood of mother leading to gestational 
diabetes. In majority of cases, it terminates with the 
termination of gestation but it increases the risk of type 2 
diabetes later in life for the mother and the child. It is 
associated with secretion of insulin by the placenta and a 
decrease in insulin sensitivity by the end of the first trimester, 
results in a transient state of insulin resistance. But it may 
prove fatal to both mother and foetus resulting into 
neuropathy, intrauterine growth retardation, premature 
delivery, neonatal jaundice; breathing difficulties in the infant 
and even still birth due to its potential teratogenicity [8]. 
According to the American Diabetes Association about 4% of 
pregnant women develop gestational diabetes [9].  
 
2.2.4 MATURITY ONSET DIABETES OF THE YOUNG: 
It is a rare monogenic type of diabetes caused due to mutation 
in any one of the genes namely hepatocyte nuclear factor 4α 
(HNF‑4α), glucokinase gene (HNF‑1α), insulin promoter 
factor‑1 (IPF‑1), HNF‑1β and NEUROD1 [2]. 70% cases of 
this kind of diabetes are associated with mutation in HNF‑1 α 
gene. It is characterized by major defect in insulin secretion 
[10]. It may be caused due to secondary factors like 
pancreatitis, Cushing’s syndrome, Klinefelter’s syndrome and 
hyperthyroidism. 
 
2.2.5 LATENT AUTOIMMUNE DIABETES IN ADULTS: 
Latent Autoimmune Diabetes in Adults (LADA) is a form of 
autoimmune (type 1 diabetes) which is diagnosed in 
individuals who are older than the usual age of onset of type 1 
diabetes (with age more than 25 years). Alternate terms that 
have been used for "LADA" include Late-onset Autoimmune 
Diabetes of Adulthood, "Slow Onset Type 1" diabetes, and 
sometimes also "Type 1.5 diabetes”. Often, patients with 
LADA are mistakenly thought to have type 2 diabetes, based 
on their age at the time of diagnosis. 
3)  RISK FACTORS AND CAUSES OF DIABETES 
Diabetes is a chronic multifactorial disorder depending on 
genetics, habits and environment of a person. According to 
study reports of the American Diabetes Association, there is 
10 to 25% chance and 50% chance of inheritance of type 2 
diabetes [3, 9]. The leading factors for type 2 diabetes are lack 
of regular exercise, weight gain and central obesity that 
involves accumulation of fat around the abdomen promoting 
insulin resistance. Consumption of simple carbohydrates, fibre 
free diet and excessive intake of soft drinks pose risk to type 2 
diabetes. Hypertension, hypercholesterolemia, asthma and 
polycystic ovarian syndrome are also linked to it. Hormonal 
disturbances particularly glucocorticoids, anabolic steroids 
and injected contraceptives may change blood glucose levels. 
Mumps, rubella and coxsackie virus infection may result into 
type 1 diabetes. 
4) DIAGNOSTIC CRITERIA 
Clinical diagnosis of Diabetes Mellitus involves following 
tests [11]: 
1. Random plasma glucose ≥ 200 mg/dl  
2. Fasting plasma glucose ≥ 126 mg/dl  
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3. Oral glucose tolerance test for gestational diabetes (measure 
of plasma glucose levels 2 hr after glucose is given orally 
>200 mg/dl) 
4. Hb A1C glycohemoglobin tests (for assessing long-term 
control of glucose) 
Another test called C-peptide test can distinguish different 
types of diabetes. Type 2 diabetes patients have C-peptide, 
which is a byproduct of insulin production, but people with 
Type 1 diabetes do not or have a very low level.  
 
5) MANAGEMENT AND TREATMENT OF DIABETES         
    MELLITUS 
 
Diabetes can be managed by diet control and exercise, oral 
hypoglycemic therapy and insulin therapy. Diet is a basic part 
of management in every case. Treatment cannot be effective 
unless adequate attention is given to ensuring appropriate 
nutrition. Diabetic patient’s diet should not contain more than 
10% saturated fats or more than 300 mg Cholesterol. There 
should be minimum intake of 20 g dietry fibres through 
regular consumption of wholegrain cereals, legumes, fruits 
and vegetables. Excessive salt intake is to be avoided. It 
should be particularly restricted in people with hypertension 
and those with nephropathy. Dietary treatment should aim at 
weight control, providing nutritional requirements, allowing 
good glycaemic control with blood glucose levels as close to 
normal as possible, correcting any associated blood lipid 
abnormalities. Regular monitoring of blood glucose 
concentration must be done by using glucometer to prevent 
diabetes associated complications. Type 1 diabetes patients are 
treated with insulin which can be administered in injectable, 
oral or possibly as inhaled forms, or with novel delivery 
systems based on nanotechnology [12, 13, 14]. Type 2 
diabetes patients who do not follow above stated management 
of diabetes show increased levels of glucose concentration 
with glycated haemoglobin (HbA1C of >6.0). In such cases 
use of anti- diabetic drugs become a necessity [15]. Type 2 
diabetes is generally treated by antidiabetic drugs like Alpha-
glucosidase inhibitors, DPP-4 inhibitors, Biguanides, 
Meglitinides, Sulfonylureas and Thiazolidinediones. These 
anti-diabetic drugs are broadly classified into four types [2]: 
 
a) Biguanides which reduce gluconeogenesis in the liver and 
include Metformin 
b) Insulin secretagogues which stimulate the pancreas to 
secrete insulin and include drugs such as sulfonylureas 
c) Insulin sensitizers which improve sensitivity of peripheral 
tissues to insulin and include thialzolidinediones  
d) Insulin/Insulin analogues which provide insulin 
exogenously in the form of recombinant insulin 
 
Certain antihypertensive like ACE inhibitors and angiotensin-
II receptor blockers and antichloestrol drugs are also 
recommended along with these drugs to prevent diabetic 
nephropathy. Synthetic amylin is employed top treat type 1 
diabetes. Glucagon kit can be used in cases of severe 
hypoglycemia or insulin shock. Research as well as 
technology developments in the field of diabetes with respect 
to its pathophysiology and management led to the 
development of more effective drugs that work upon incretin 
system and include injectable glucagon‑like peptide‑1 agonists 
(potentially stimulate insulin secretion) and oral dipeptidyl 
peptidase‑4 (DPP‑4) inhibitors (like Linagliptin, Saxagliptin, 
Sitagliptin, Vildagliptin inhibit the DPP‑4 enzyme, and 
increase the circulating incretin hormone GLP‑1) [16, 17].In 
addition, sodium‑glucose transport protein‑2 (SGLT‑2) 
inhibitors aiming to block renal glucose re‑absorption via the 
SGLT‑2 transporter are also being developed [18].  Type 1 
diabetes can be treated by transplantation of whole pancreas or 
pancreatic islets from suitable donor but transplantation 
therapy is challenged by organ rejection reaction even in the 
presence of immunosuppressant [19]. Furthermore, researches 
are being carried out to develop the stem cell that can generate 
insulin producing β-cells [20, 21]. General precautionary 
measures like dietary management, exercise, foot and skin 
care, regular monitoring of blood glucose and cholesterol may 
prove helpful in the avoidance of diabetes. 
 
6) COMPLICATIONS OF DIABETES MELLITUS 
 
Diabetes is commonly referred as silent killer disease as it 
attacks on multiple organs like heart, kidney, muscles, eyes 
and immune system leading to their malfunctioning or failure. 
It may involve damage to the small blood vessels (diabetic 
angiopathy) and contribute to diabetic neuropathy, 
nephropathy and retinopathy. Diabetic patients have 2 to 4 
fold increased risk of developing coronary heart disease, 
atherosclerosis and stroke. T2DM patients generally show 
hypertension, hypercholesterolemia and hyperinsulinemia. 
15% of diabetics develop foot ulcers and 5-15% of patients 
with foot ulcers need amputations.16% of diabetics are 
suffering from kidney failures. Diabetic retinopathy caused 
1.9% of moderate or severe visual impairment globally and 
2.6% of blindness in 2010. It is the second leading cause of 
blindness and renal disease worldwide resulting into glaucoma 
and cataracts [22, 23]. However, retinopathy rates are higher 
among: people with type 1 diabetes; people with longer 
duration of diabetes; Caucasian populations; and possibly 
among people of lower socioeconomic status [24]. The most 
commonly occurring long term complication of diabetes is 
neuropathy which affects more than 60% of diabetic patients 
resulting into loss of hearing/visual sensation, pain, weakness 
and even limb amputations [25, 26].Peripheral neuropathy 
often causes pain or numbness in the limbs and autonomic 
neuropathy can impede digestion and contribute to sexual 
dysfunction and incontinence. Diabetics show more risk of 
memory loss, dementia, Alzheimer’s disease and other 
cognitive deficits. Diabetic nephropathy is the leading cause of 
end stage renal failure and marked by progressive rise of 
albumin in urine, increase in the glomerular blood pressure as 
well as urinary tract infections [27]. It requires treatment with 




The prevalence of diabetes is increasing at a very fast rate as 
indicated by world diabetes statistics that number of people 
living with diabetes has jumped from 108 million in 1980 to 
422 million in 2014. In order to have check on the global 
spread of diabetes, there is urgent need to develop new 
strategies involving establishment of mechanisms for resource 
allocation effective leadership and advocacy for an integrated 
non-communicable diseases programme, with specific 
attention to diabetes. In addition to this, there is need for 
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production of antidiabetic drugs having more efficacies along 
with effective developments in pancreas or pancreatic islet 
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